Abstract: A PIN device includes: a first doped layer, a second doped layer, and an intrinsic layer between the first doped layer and the second doped layer, where the second doped layer includes a body portion and an electric field isolating portion at least partially enclosing the body portion; and the electric field isolating portion is doped differently from the body portion.

Abstract: A stretchable display panel having a plurality of encapsulated islands and a plurality of bridges connecting the plurality of encapsulated islands is provided. The stretchable display panel includes a stretchable base substrate; a flexible base wall on the stretchable base substrate, the flexible base wall substantially enclosing a substantially enclosed space; an adhesive layer on the stretchable base substrate and substantially enclosed in the substantially enclosed space; and a plurality of light emitting elements on a side of the adhesive layer away from the stretchable base substrate. A respective one of the plurality of encapsulated islands includes at least one of the plurality of light emitting elements encapsulated therein on the stretchable base substrate.

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, ester, stereoisomer, tautomer, solvate, hydrate, or combination thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).

Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts and esters thereof: pharmaceutical compositions comprising these compounds and methods of using these compounds to treat or prevent a disease or disorder mediated as FXR modulators. Specifically, the present invention relates to isoxazole derivatives useful as agonists for FXR, and methods for their preparation and use.

Abstract: An analytics device for monitoring maintenance on an elevator system performed by an individual including: a processor; and a memory including computer-executable instructions that, when executed by the processor, cause the processor to perform operations, the operations including: capturing a first video stream using a first video camera; extracting sequences from at least the first video stream; extracting features from the sequences; and analyzing, using a long short-term memory model, the sequence to determine whether the maintenance performed on the elevator system by the individual is performed correctly.

Abstract: The present disclosure is related to an array substrate. The array substrate may include a base substrate; a plurality or light-emitting devices on the base substrate; a photosensitive device between the light-emitting devices and the base substrate; and a refractive layer between the photosensitive device and the light-emitting devices. The refractive layer may be at a distance from the photosensitive device, and the refractive layer may cover at least a gap region between the adjacent light-emitting devices. A refractive index of the refractive layer may be larger than a refractive index of a film layer in the gap region between the refractive layer and the photosensitive device, and an orthographic protection of the photosensitive device on the base substrate may at least partially overlap an orthographic projection of the light-emitting devices on base substrate.

Abstract: The present invention provides compounds represented by Formula I, or pharmaceutically acceptable salts, stereoisomers, solvates, hydrates or combination thereof, The invention also provides pharmaceutical compositions comprising these compounds and methods of using this compounds for treating FXR-mediated or TGR5-mediated diseases or conditions.

Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof: which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.

Abstract: A light-emitting unit and a method for manufacturing the same are provided. The light-emitting unit includes a first semiconductor layer, a light-emitting layer and a second semiconductor layer that are distributed in a stacking manner. At least one of the first semiconductor layer or the second semiconductor layer is at least in contact with a part of layer surfaces and a part of side of the light-emitting layer, the first semiconductor layer is insulated from the second semiconductor layer, and one of the first semiconductor layer and the second semiconductor layer is an N-type semiconductor layer, and the other is a P-type semiconductor layer. The present disclosure is conducive to increasing the light-emitting area and the light extraction efficiency of the light-emitting unit.

Abstract: Disclosed herein is a cold spray system. The cold spray system comprises a nozzle unit comprising a coating nozzle member, configured to apply at least a portion of a metallic coating to a substrate. The cold spray system is configured to pre-heat the substrate before application of the at least a portion of the metallic coating to the substrate. Also disclosed herein is a method for applying a coating via a cold spray technique.

Abstract: The present disclosure provides an inorganic light-emitting diode chip, a method for preparing the same, and a display substrate. The inorganic light-emitting diode chip includes: an undoped gallium nitride layer and a light-emitting unit arranged on the undoped gallium nitride layer, the light-emitting unit includes a first light-emitting subunit including a first N-type gallium nitride layer, a first multi-quantum well layer and a first P-type gallium nitride layer that are sequentially arranged, and a second light-emitting subunit including a second P-type gallium nitride layer, a second multi-quantum well layer and a second N-type gallium nitride layer that are sequentially arranged on a surface of the first P-type gallium nitride layer; an orthogonal projection of the second multi-quantum well layer on the undoped gallium nitride layer is smaller than an orthogonal projection of the first multi-quantum well layer on the undoped gallium nitride layer.

Abstract: The present disclosure provides a polarizing device and a method for preparing the same, a display substrate, and a display device. The polarizing device includes: a base substrate, a metal wire grid, and an anti-reflection layer, in which the metal wire grid is arranged on the base substrate, the anti-reflection layer is arranged on the surface of the metal wire grid away from the base substrate, and the anti-reflection layer is a carbon film layer.

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, ester, stereoisomer, tautomer, solvate, hydrate, or combination thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).

Abstract: Disclosed is a flexible display substrate, including: a substrate base layer, peripheral side edges of the substrate base layer having a first stepped structure having a process performance, the first stepped structure being configured to enable a film layer covering the first stepped structure to be easily broken at the stepped structure when a force is applied; a functional layer provided on the substrate base layer and exposed to the outside of the first stepped structure; and an inorganic encapsulation layer covering side edges of the functional layer and extending to the first stepped structure of the side edges of the substrate base layer.

Abstract: The present application discloses a semiconductor apparatus, a pixel circuit and a control method thereof. The semiconductor apparatus comprises: an active layer; a first insulating layer; a first gate and a second gate overlapping with a portion of the active layer with the first insulating layer interposed therebetween, respectively; a first electrode, a second electrode and a third electrode, the first electrode and the second electrode are electrically connected with a first portion and a second portion of the active layer, respectively, the third electrode is used to be electrically connected with a photosensitive device, wherein the third electrode is electrically connected with the first gate or the second gate; or the third electrode is electrically connected with a third portion of the active layer.

Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts and esters thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV) or HMPV. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV or HMPV infection. The invention also relates to methods of treating an RSV or HMPV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Abstract: An intelligent decision-making device and method for UAV formation information interaction topologies in communication interference, comprising: acquiring a three-dimensional UAV formation without communication interference, an initial communication network D1 and an initial information interaction topology T1; acquiring communication links A0 interrupted by UAV formation with communication interference; acquiring interrupted communication links A1 in T1 based on A0 and T1; determining whether A0 affects T1; if not, T1 being the final information interaction topology; if yes, acquiring substitute reverse arcs of A1 and substituting A1 with them to obtain an information interaction topology T2; determining whether T2 is a three-dimensional persistent graph; if yes, T2 being the final information interaction topology; if not, acquiring an undirected graph R1 corresponding to T2; acquiring spare edges based on R1; and adding an arc corresponding to a spare edge in T2 based on the spare edges to obtain a final in

Abstract: A photodetector (300) includes a first electrode (313) and a second electrode (314) on a base substrate (100); a light-sensitive layer (311) between the first electrode (313) and the second electrode (314); and a light-trapping layer (312) between the light-sensitive layer (311) and the base substrate (100), wherein a surface of the light-trapping layer (312) opposite from the base substrate (100) comprises a plurality of first recessed portions.

Abstract: The present invention discloses compounds of Formula (Ia), and pharmaceutically acceptable salts, thereof: which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (Ia) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (Ia) or a pharmaceutically acceptable salt thereof.